

A new regulator of pathogenicity (*bvIR*) is required for full virulence and tight microcolony formation in *Pseudomonas aeruginosa*

Ronan R. McCarthy,¹ Marlies J. Mooij,^{1†} F. Jerry Reen,¹ Olivier Lesouhaitier² and Fergal O’Gara^{1,3}

Correspondence

Fergal O’Gara
f.ogara@ucc.ie
Marlies J. Mooij
marlies.mooij@mumc.nl

¹BIOMERIT Research Centre, School of Microbiology, University College Cork, Cork, Ireland

²Laboratory of Microbiology Signals and Microenvironment LMSM EA4312, University of Rouen, 55 rue Saint Germain, 27000 Evreux, France

³Curtin University, School of Biomedical Sciences, Perth, WA, Australia

LysR-type transcriptional regulators (LTTRs) are the most common family of transcriptional regulators found in the opportunistic pathogen *Pseudomonas aeruginosa*. They are known to regulate a wide variety of virulence determinants and have emerged recently as positive global regulators of pathogenicity in a broad spectrum of important bacterial pathogens. However, in spite of their key role in modulating expression of key virulence determinants underpinning pathogenic traits associated with the process of infection, surprisingly few are found to be transcriptionally altered by contact with host cells. BvIR (PA14_26880) an LTTR of previously unknown function, has been shown to be induced in response to host cell contact, and was therefore investigated for its potential role in virulence. BvIR expression was found to play a pivotal role in the regulation of acute virulence determinants such as type III secretion system and exotoxin A production. BvIR also played a key role in *P. aeruginosa* pathogenicity within the *Caenorhabditis elegans* acute model of infection. Loss of BvIR led to an inability to form tight microcolonies, a key step in biofilm formation in the cystic fibrosis lung, although surface attachment was increased. Unusually for LTTRs, BvIR was shown to exert its influence through the transcriptional repression of many genes, including the virulence-associated *cupA* and *alg* genes. This highlights the importance of BvIR as a new virulence regulator in *P. aeruginosa* with a central role in modulating key events in the pathogen–host interactome.

Received 22 November 2013

Accepted 2 May 2014

INTRODUCTION

Cystic fibrosis (CF) is the most prevalent autosomal recessive disorder in the Caucasian population. The leading cause of morbidity among CF patients is loss of lung function due to chronic bacterial infection (Koch & Hoiby, 1993). While a range of different bacteria establish infections in the CF lung throughout infancy, many of these are often treated successfully with antibiotics (Harrison, 2007). *Pseudomonas aeruginosa*, however, is capable of avoiding eradication, and becomes the dominant species of bacteria in the lungs from the late teens onwards. These chronic infections result in *P. aeruginosa* being the leading cause of

morbidity and mortality among CF patients (Lyczak *et al.*, 2002). To establish a chronic lung infection, *P. aeruginosa* utilizes a wide range of virulence determinants, the production of which it controls through interconnection of global and local regulatory networks.

LysR-type transcriptional regulators (LTTRs) are the most common transcriptional regulators found in *Pseudomonas* with 125 putative LTTRs having been identified in the *Pseudomonas* genome (Schell, 1993). Several *P. aeruginosa* virulence genes have been shown to be under the control of LTTRs, for example MexT and MvfR, both of which regulate a range of virulence-associated factors, such as elastase, phospholipase, homoserine lactone and the *Pseudomonas* quinolone signal (Tian *et al.*, 2009; Wade *et al.*, 2005). The key enzyme in alginate synthesis, AlgD, has also been shown to be under the control of an LTTR, CysB (Delic-Attree *et al.*, 1997). As such, LTTRs are rapidly emerging as a key family of regulators influencing a wide range of virulence processes in *P. aeruginosa* (Reen *et al.*, 2013b).

[†]Present address: Maastricht University Medical Centre, Maastricht, The Netherlands.

Abbreviations: CF, cystic fibrosis; EMSA, electromobility shift assay; LTTR, LysR-type transcriptional regulator; MCS, multiple cloning site; T3SS, type III secretion system.

Two supplementary tables and four supplementary figures are available with the online version of this paper.

In-depth functional analysis of uncharacterized host-activated LTTRs is necessary to fully elucidate the network of regulation influencing *P. aeruginosa* pathogenicity. Previously, phylogenetic analysis of LTTRs in the genus *Pseudomonas* identified several distinct clusters (Reen *et al.*, 2013a). While the analysis was based solely on amino acid sequence relationships, a pattern of interconnected regulation or cross-talk was observed. This was particularly evident in the regulation of pathogenic traits. However, for the most part these LTTRs were transcriptionally silent during co-culture experiments with host cells (Frisk *et al.*, 2004). To identify potential LTTRs that are actively involved in the host–pathogen interaction, publicly available transcriptome profiles were interrogated and PA2877 (PA14_26880 homologue in *P. aeruginosa* clinical isolate PA14) was shown to be upregulated in response to epithelial cells (Frisk *et al.*, 2004). To investigate its potential role in pathogenicity, PA14_26880 was characterized at both the molecular and the phenotypic level in *P. aeruginosa* PA14.

This LTTR was found to have a significant influence on the expression of acute determinants, with mutation of PA14_26880 leading to enhanced killing of the nematode acute model of infection. Our data support a role for PA14_26880 as a key regulator of virulence-associated phenotypes and pathogenesis in *P. aeruginosa*.

METHODS

Strains, plasmids and media. The strains and plasmids used in this study are listed in Table 1. All experiments were performed in wild-type *P. aeruginosa* strain UCBPP-PA14 or mutants obtained from the non-redundant PA14 insertion mutant library – PA14NR Set (Liberati *et al.*, 2006). All strains were routinely cultured in Luria–Bertani (LB; Sigma) broth at 37 °C with shaking at 150 r.p.m. unless otherwise stated. Antibiotics were added to cultures where required at the following concentrations: *Escherichia coli* – kanamycin 25 µg ml⁻¹, tetracycline 20 µg ml⁻¹, chloramphenicol 20 µg ml⁻¹; *P. aeruginosa* – tetracycline 25 µg ml⁻¹, gentamicin 20 µg ml⁻¹, streptomycin 100 µg ml⁻¹.

Table 1. Strains/plasmids used in this study

Name	Description	Reference/source
Plasmids		
pMP190	IncQ origin, low-copy-number <i>lacZ</i> fusionvector; Cm ^R St ^R	Spaink <i>et al.</i> (1987)
pMP190_ <i>exsC</i>	Contains promoter region of <i>exsC</i> cloned into MCS	This study
pME6032	pVS1-p15A origin, <i>lacI^P</i> -Ptac expression vector, Tc ^R	Heeb <i>et al.</i> (2000)
pME <i>bvIR</i>	pME6032 plasmid with <i>bvIR</i> (PA14_26880) gene cloned into MCS	This study
pMS402	Promoterless <i>lux</i> operon downstream of MCS, Tm ^R	Duan & Surette (2007)
pMS- <i>bvIRp</i>	Contains promoter region of <i>bvIR</i> cloned into MCS	This study
pRK600	Mobilization plasmid helper	Keen <i>et al.</i> (1988)
pCR2.1-TOPO	PCR cloning vector, Ap ^R Km ^R	Invitrogen
pET28a	T7 promoter-driven His-tag protein expression vector, Km ^R	Novagen
pET28ab <i>bvIR</i> Cter	C-terminal His-tagged <i>bvIR</i> in pET28a	This study
Strains		
PA14 pME6032	Wild-type PA14, <i>P. aeruginosa</i> clinical isolate, containing empty plasmid pME6032	This study
PA14:: <i>bvIR</i> pME6032	PA14 with Tn5 Mariner Transposon in <i>bvIR</i> , containing empty plasmid pME6032	This study
PA14:: <i>bvIR</i> pME <i>bvIR</i>	PA14 with Tn5 Mariner Transposon in <i>bvIR</i> ORF, pME6032 plasmid with <i>bvIR</i> gene cloned into MCS	This study
PA14 pMS <i>bvIR</i>	PA14, containing pMS plasmid with <i>bvIR</i> promoter cloned into MCS	This study
PA14:: <i>bvIR</i> pMS	PA14 with Tn5 Mariner Transposon in <i>bvIR</i> , containing empty plasmid pMS	This study
PA14:: <i>bvIR</i> pMS- <i>bvIRp</i>	PA14 with Tn5 Mariner Transposon in <i>bvIR</i> , containing pMS plasmid with <i>bvIR</i> promoter cloned into MCS	This study
PA14 pME6032 pMP190_ <i>exsC</i>	Previously described strain containing pMP190_ <i>exsC</i>	This study
PA14:: <i>bvIR</i> pME6032 pMP190_ <i>exsC</i>	Previously described strain containing pMP190_ <i>exsC</i>	This study
PA14:: <i>bvIR</i> pME <i>bvIR</i> pMP190_ <i>exsC</i>	Previously described strain containing pMP190_ <i>exsC</i>	This study
PA14:: <i>bvIA</i>	Wild-type PA14 with Tn5 Mariner Transposon in <i>bvIA</i> ORF	Liberati <i>et al.</i> (2006)
<i>E. coli</i> HB101	Cloning and subcloning host	Sambrook & Russell (2001)
<i>E. coli</i> Top10	Cloning and subcloning host	Invitrogen
<i>E. coli</i> DH5α	Cloning and subcloning host	Boyer & Roulland-Dussoix (1969)
<i>E. coli</i> OP50	<i>Caenorhabditis elegans</i> non-toxic strain	Blier <i>et al.</i> (2011)
BL21-CodonPlus BL21(DE3)-RIPL	Protein expression host	Merck

Generation of plasmids used in this study. All PCRs were performed in a final volume of 20 μ l using *Pfu* Proofreading polymerase (Promega) according to the manufacturer's recommendations. Primers were designed based on the PA14 genome sequence (NC_008463) and can be found in Table S1 (available in the online Supplementary Material). The PCR products were then A-tailed using 100 μ M dATP (Applied Bioscience) and AccuPrime polymerase (Roche Applied Science) and incubated at 94 °C for 2 min followed by 68 °C for 20 min, after which the PCR products were cloned into pCR2.1-TOPO (Invitrogen) according to the manufacturer's recommendations. All constructs were verified by sequence analysis (GATC Biotech), and subsequently cloned into their respective host plasmids and finally transferred from *E. coli* DH5 α (Boyer & Roulland-Dussoix, 1969) to *P. aeruginosa* by triparental mating using the helper plasmid pRK600 as described by de Lorenzo & Timmis (1994) and Keen *et al.* (1988). The T4 DNA ligase and all restriction enzymes used in this study were purchased from Roche Applied Sciences and were used according to the manufacturer's recommendations.

To generate plasmid pMEbvIR, the PA14_26880 ORF was amplified using primers bvIR OEF and bvIR OER, which contain incorporated *Bgl*II and *Kpn*I restriction sites, respectively, and was ligated into the pME6032 multiple cloning site (MCS) downstream of the P_{tac} promoter (Heeb *et al.*, 2000). The vector was then transformed by heat shock into *E. coli* Top10 Cloning and subcloning host (Invitrogen).

To generate an *exsC* promoter expression construct, a 340 bp fragment upstream of *exsC* was amplified with *exsC* TFF and *exsC* TFR, which incorporated the *Xba*I and *Kpn*I restriction sites, respectively. The *Xba*I–*Kpn*I *exsC* fragment was cloned into *Xba*I–*Kpn*I-digested pMP190 (Spaink *et al.*, 1987) to produce pMP190_*exsC*.

To construct a plasmid expressing a His-tagged BvIR protein, the *bvIR* ORF was amplified using primers BvIR His F and BvIR His R, which incorporate *Nco*I and *Hind*III restriction sites, respectively. Finally, the amplicon was cloned into the MCS of pET28a to yield pET28abvIRH6C, which expressed a C-terminal His-tagged BvIR protein.

Transcriptional fusions to *luxCDABE* were generated by cloning the promoter regions of PA14_26880, amplified by PCR using primer sets bvIR TFF and BvIR TFR. The amplicon was flanked by *Xho*I–*Bam*HI restriction sites, allowing it to be ligated into the sites *Xho*I–*Bam*HI of pMS402 (Duan & Surette, 2007). Luminescence was measured over time using a Tecan GENios Microplate Reader.

β -Galactosidase assay. For the β -galactosidase assay, *P. aeruginosa* cultures were grown overnight in LB broth supplemented with appropriate antibiotics. IPTG was added at a concentration of 1 mM for all pME6032 derivative plasmids. Cells were diluted to an OD₆₀₀ of 0.05 in 20 ml and incubated at 37 °C at 150 r.p.m. Cells were recovered at the exponential phase of growth and β -galactosidase assays were performed as described by Miller (1972). Data are the mean of three independent biological replicates.

Microcolony formation assay. Artificial sputum medium (ASM) was prepared as described by Sriramulu *et al.* (2005). ASM (1 ml) was inoculated to an OD₆₀₀ of 0.05 with an overnight culture of *P. aeruginosa* PA14 in 24-well cell-culture plates (Sarstedt). IPTG was added at a concentration of 1 mM for all pME6032 derivative plasmids. Plates were then incubated at 37 °C at 150 r.p.m. for 72 h. Three independent biological replicates were performed, and representative results are shown.

Caenorhabditis elegans assays. The *C. elegans* assay was performed as described by Blier *et al.* (2011). In brief, *C. elegans* was maintained under standard culturing conditions at 22 °C on nematode growth medium (all per litre, 3 g NaCl, 2.5 g peptone, 17 g

agar, 5 mg cholesterol, 1 ml 1 M CaCl₂, 1 ml 1 M MgSO₄, 25 ml 1 M KH₂PO₄) agar plates with *E. coli* OP50 as a food source (Sulston & Hodgkin, 1988). Synchronous cultures of worms were generated. Pathogen lawns used for *C. elegans* survival assays were prepared by spreading 50 μ l *P. aeruginosa* strains corrected to an OD₆₀₀ of 1 (mutant vs. complemented). The plates were incubated overnight at 37 °C and then placed at room temperature for 4 h. Between 15 and 20 L4 synchronized worms were harvested with M9 solution, placed on 35 mm assay Petri dishes and incubated at 22 °C. Worm survival was scored at 1 h, 24 h and each subsequent day, using an Axiovert S100 optical microscope (Zeiss) equipped with a Nikon digital camera DXM 1200F (Nikon Instruments). The worms were considered dead when they remained static without grinder movements for 20 s. Standard ethical procedures were used. The results are expressed as the percentage of living worms and are the mean of three independent biological assays.

Attachment assay. Due to the viscous nature of ASM, it was not feasible to accurately determine levels of bacterial attachment in this medium. Therefore, M63 medium was prepared as described by O'Toole & Kolter (1998) and used to assess bacterial attachment. Strains were inoculated from a fresh overnight culture into 1 ml of M63 broth in 24-well microtitre plates (Starstedt) at an OD₆₀₀ of 0.25. IPTG was added to the medium at a concentration of 1 mM. Cultures were incubated at 37 °C for 1 h statically. OD₆₀₀ was measured to ensure no difference in growth. Cultures were removed and wells washed three times with 1.2 ml LB. Then, 1.3 ml of 0.1% crystal violet (Sigma) was added and incubated at room temperature for 10 min. The crystal violet was removed and the wells were washed five times with distilled H₂O. Plates were then dried at 37 °C for 2 h. Then, 1.5 ml of 96% EtOH was added to each well and incubated at room temperature for 15 min. One hundred microlitres was then taken from each well and added to a clean 96-well plate (Corning) and OD₅₇₀ was measured.

Flow cell biofilm assay. Flow cell chambers with individual channel dimensions of 1 \times 4 \times 40 mm were used. The flow system was assembled and prepared as described by Gjermansen *et al.* (2005). Overnight cultures of *Pseudomonas* strains were inoculated as single colonies into 5 ml of M63 medium (O'Toole & Kolter (1998) and shaken (180 r.p.m.) overnight at 37 °C. Bacteria were grown in M63 medium throughout the flow cell experiment. The flow chambers were inoculated by injecting 250 μ l overnight culture diluted to an OD₆₀₀ of 1 into each flow channel using a small syringe. After inoculation, the flow channels were left without flow for 1 h, after which medium flow was started using a Watson Marlow 205S peristaltic pump. The mean flow velocity in the flow chambers was 0.2 mm s⁻¹, corresponding to a laminar flow with a Reynolds number of 0.02. The flow cell biofilm system was incubated at 30 °C throughout the experiment. Bacteria were stained using 5 μ M SYTO 9 (Invitrogen). Visualization of the biofilm was performed using a Zeiss LSM5 confocal laser scanning microscope equipped with the 488 nm laser lines to excite SYTO 9. Three independent biological replicates were performed. Images were processed using the Imaris 6.0.2 Software suite.

RNA isolation, global expression analysis, cDNA synthesis and quantitative real-time PCR. RNA was extracted from exponential-phase cultures (OD₆₀₀ of 0.7–0.8) of PA14 pME6032, PA14::bvIR pME6032 and PA14::bvIR pME6032_bvIR using the RNeasy minikit (Qiagen). Genomic DNA was removed using TURBO DNase (Ambion). Isolated RNA was sent to DNAVision for further analysis. RNA quality was assessed using a Bioanalyser Agilent 2100 at DNAVision. cDNA synthesis, fragmentation and terminal labelling preceded hybridization on Affymetrix GeneChip *P. aeruginosa* genome arrays according to the Affymetrix guidelines. GeneSpring GX software was used to analyse raw data following the manufacturer's guidelines.

In brief, the raw data were normalized using the robust multiarray average algorithm. An empirical Bayesian unpaired comparison (moderated *t*-test, $P < 0.05$) was carried out to generate a list of genes with significantly altered expression between the test strains of greater than twofold.

For quantitative real-time PCR analysis, cDNA was synthesized using AMV reverse transcriptase (Promega) and random primers (Invitrogen). Real-time primers were designed utilizing the Universal Probe Library Assay Design Center (UPL, Roche). Real-time PCR was conducted on a Chromo4 Continuous Fluorescence Detector (MJ Research) using FastStart TaqMAN Probe Master and probes from the Universal ProbeLibrary (UPL, Roche) according to the manufacturer's recommendations. All data presented are relative to the housekeeping gene *proC*, and are the mean of three independent biological replicates.

His-tag purification of BvIR. The pET28abvIRH6C construct was transformed into the *E. coli* expression host strain BL21-CodonPlus BL21(DE3)-RIPL (Merck) and grown at 37 °C with shaking at 150 r.p.m. in 250 ml LB medium containing kanamycin (50 mg ml⁻¹) until an OD₆₀₀ of 0.8 was reached. At this point 1 mM IPTG was added to the culture to induce expression of the His-tagged BvIR protein. After 4 h, cells were harvested by centrifugation at 5000 g at 4 °C and stored at -70 °C overnight. Cell pellets were subsequently thawed and resuspended in CelLytic B II buffer (10 ml per gram of cell paste) with 50 units benzonase ml⁻¹, 0.2 mg lysozyme ml⁻¹ and 100 µl of Protease Inhibitor Cocktail (all concentrations relative to 1 g of cell paste). Protein extract was applied to a Poly-4 Prep Chromatography Column (Bio-Rad) containing 1 ml of HIS-Select Nickel Affinity Gel. The gel was washed with 2 ml of sterile de-ionized water and equilibrated with 5 ml of wash buffer (100 mM HEPES, pH 7.5, 10 mM imidazole). Following washing and equilibration steps, the crude protein extract (10 ml) was passed through the column by gravity flow. Proteins which bound to the resin were washed twice with 5 ml wash buffer and purified His-tagged BvIR protein was eluted in wash buffer containing imidazole at the following concentrations (1, 10, 50, 100, 250, 500 and 750 mM). The purity of the purified BvIR protein was assessed by SDS PAGE as described by Sambrook & Russell (2001). Protein concentrations were determined by the Bio-Rad protein assay (Bradford, 1976) and purified protein aliquots were used for electromobility shift assays (EMSAs). All chemicals were purchased from Sigma Aldrich unless stated otherwise.

EMSA. First, the labelled promoter DNA fragments were generated by amplification of the promoter fragments with infrared-labelled primers (Eurofins MWG Operon) (Table 1) using *Pfu* Proofreading polymerase (Promega), according to the manufacturer's recommendations in a total volume of 20 µl. Amplified DNA fragments were visualized by agarose gel electrophoresis and subsequently purified using a gel extraction kit (Qiagen), according to the manufacturer's recommendations. The *bvIR/bvIA* IRF and *bvIR/bvIA* IRR primer set was used to construct the *blvA-bvIR* intergenic region, whereas the truncated *blvA-bvIR* intergenic region was amplified using *bvIR/bvIA* IT IRF and *bvIR/bvIA* IT IRR primers. The *oprF-sigX* intergenic region was amplified using the primers OprF IRF and OprF IRR. The primer sets used to amplify other promoter regions included in this study are presented in Table S1. The final EMSA reaction volume was 20 µl, containing varying concentrations of purified BvIR protein (50–2000 nM) in the presence of 10 fmol of labelled promoter DNA fragment in EMSA binding buffer [20 mM HEPES, pH 7.6, containing 30 mM KCl, 5 mM (NH₄)₂SO₄, 1 mM EDTA, 1 mM DTT, 0.2 % (w/v) Tween 20 and 5 µg poly[d(I-C)] ml⁻¹]. The reaction was incubated at 28 °C for 40 min, and samples were then separated by electrophoresis on 6 % (v/v) native polyacrylamide gel and visualized on an Odyssey Infrared Imaging System (Li-COR Biosciences). Control binding reactions were performed with extracts from *E. coli*

BL21-CodonPlus BL21(DE3)-RIPL cells harbouring the pET28a vector control.

Bioinformatic analysis. DNA sequence was obtained from the PA14 genome sequence (NC_008463) and used as bait in sequential BLASTN and BLASTP searches. Potential BvIR binding motifs were identified using the DNA Motif Search tool at www.pseudomonas.com. All amino acid sequences were aligned with CLUSTAL W and phylogenetic analysis was performed using the MEGA5 software program. Trees were generated using the neighbour-joining algorithm (p-Distance) using as outgroup *P. aeruginosa* PA2206, a non-homologous LTTR. Minimum bootstrap support values ≥95 % were enforced for this analysis.

Statistical analysis. For the *C. elegans* assay, survival was calculated by using the Kaplan–Meier method, and survival differences were tested for significance by using the log-rank test (GraphPad Prism version 4.0, GraphPad Software) over three independent biological replicates. For all other experiments outlined here, statistical analysis was performed using a two-tailed paired Student's *t*-test. Differences were considered significant if the *P*-value was ≤0.05 over three independent biological replicates.

RESULTS

A new repressor (PA14_26880) of the type III secretion system

The process of infection by *P. aeruginosa* is primarily characterized by two distinct phases. Initial colonization through expression of acute virulence determinants is followed by a switch to a chronic biofilm state that is practically impossible to eradicate. The involvement of LTTRs in this process remains poorly understood in spite of the fact that they represent the largest family of transcriptional regulators in *P. aeruginosa*. Analysis of the publicly available transcriptome datasets revealed that PA2877 (PA14_26880 homologue in *P. aeruginosa* clinical isolate PA14) is transcriptionally altered in response to epithelial cell contact, suggesting that it may play a role in *P. aeruginosa* pathogenicity. Transcriptional analysis was used to determine if PA14_26880 exerted a regulatory influence over the acute-associated type III secretion system (T3SS). The promoter region of the *exsCDBA* operon, containing the T3SS master regulator ExsA, was cloned upstream of a promoterless *lacZ* gene into pMP190, resulting in pMP190_*exsC*. β-Galactosidase assays verified that T3S was elevated 1.7-fold (Student's *t*-test, $P < 0.05$) in the PA14_26880 transposon mutant derived from the non-redundant PA14 insertion mutant library (Liberati *et al.*, 2006) (Fig. 1a). This elevated transcription was restored to wild-type levels through complementation with the PA14_26880 ORF cloned into the inducible plasmid pME6032 (Fig. 1a).

PA14_26880 promotes tight microcolony formation

Having established a role for PA14_26880 in the regulation of T3S, the possibility that this transcriptional regulator




Fig. 1. (a) Elevated levels of T3S in a PA14₂₆₈₈₀ mutant. Expression from pMMP190_{exsC} in PA14 pME6032, PA14::PA14₂₆₈₈₀ pME6032 and PA14::PA14₂₆₈₈₀ pME PA14₂₆₈₈₀ was assessed by performing β -galactosidase assays on cells that were recovered at the exponential phase of growth. Fold change is relative to wild-type levels. All measurements are in Miller units. Data shown are mean values of three biological experiments with SD as error bars. *Student's *t*-test, $P < 0.05$. (b) PA14₂₆₈₈₀ has a role in tight microcolony formation. Tight microcolony formation was assessed by growing strains in ASM for 72 h in 24-well plates. Tight microcolony formation is seen as dark non-surface-attached aggregates, which are highlighted by a white arrow. These tight microcolonies project up into the well but are not attached to any surface. Complete loss of tight microcolony formation is observed in PA14::PA14₂₆₈₈₀ pME6032. The image shown is a representative of at least three independent biological replicates. (c) PA14₂₆₈₈₀ plays a role in attachment. Levels of bacterial attachment were assessed using a crystal violet staining assay. Increased levels of attachment observed in PA14::PA14₂₆₈₈₀ pME6032. *Student's *t*-test, $P < 0.05$. (d) PA14₂₆₈₈₀ plays a role in attachment. To confirm the hyperattachment phenotype observed in the crystal violet assay and to ensure that this was not due to increased production of components of the biofilm matrix, flow cell biofilm analysis was performed. This analysis confirmed that a PA14₂₆₈₈₀ mutant indeed attaches to an abiotic surface at a much higher level than wild-type cells. Images were taken after 24 h of incubation. Cells were stained with the DNA-specific SYTO9 dye. Images were processed using the Imaris 6.0.2 Software suite. Bars, 15 μ m.

might also modulate biofilm formation was subsequently investigated. Biofilm formation and T3S have previously been shown to be inversely regulated, although the mechanism underpinning this observation has not been fully elucidated (Furukawa *et al.*, 2006). *P. aeruginosa* has been shown to form a tight microcolony in the CF lung. This behaviour differs from the classical definition of a biofilm as surface attachment is not required (Sriramulu *et al.*, 2005; Worlitzsch *et al.*, 2002). The influence of PA14₂₆₈₈₀ on this host-specific mode of biofilm formation was assessed in a synthetic medium that mimics the sputum found in the CF lung (Sriramulu *et al.*, 2005). A PA14₂₆₈₈₀ transposon

mutant was unable to form tight microcolonies in this ASM. Complementation with pME*bvlR* restored the ability of a PA14₂₆₈₈₀ mutant to form tight microcolonies. These data suggest that PA14₂₆₈₈₀ is integral to the formation of non-surface-attached biofilms such as those found in the CF lung (Fig. 1b). Interestingly, the PA14₂₆₈₈₀ mutant exhibited increased levels of abiotic surface attachment, which was restored to wild-type levels through complementation (Fig. 1c). Flow cell biofilm analysis confirmed the hyperattachment phenotype associated with a PA14₂₆₈₈₀ mutant (Fig. 1d). Assays of extracellular matrix components such as rhamnolipid and extracellular DNA (data not

shown) were performed and demonstrated no difference between the wild-type and mutant, suggesting that this increased attachment is not due to an alteration in the production of biofilm matrix components. This increased attachment phenotype is consistent with the PA14_26880 mutant cells being unable to self-aggregate in a tight microcolony. The negative regulation of T3SS and promotion of tight microcolony formation by PA14_26880 suggests a role in the chronic phase of *P. aeruginosa* infection within the host. Given the role of PA14_26880 in these key virulence phenotypes it is hereafter referred to as BvIR (Biofilm and Virulence LysR Regulator).

BvIR plays a key role in virulence in the *C. elegans* model of infection

Having established that BvIR plays a role in the modulation of key virulence determinants, it was hypothesized that it may play a role in the overall pathogenic potential of *P. aeruginosa*. To investigate this, the nematode model of infection *C. elegans* was utilized. To ensure isogenicity, the *bvIR* mutant was compared with the complemented pME*bvIR* strain. The presence of BvIR led to a significant reduction in virulence at each time point (Student's *t*-test, $P < 0.01$) (Fig. 2), suggesting a significant role in *P. aeruginosa* pathogenesis. Therefore, BvIR was functionally characterized to elucidate the molecular mechanisms underlying this key role in pathogenicity.

BvIR negatively regulates the expression of a divergent gene *bvIA* and auto-regulates its own expression

To identify the pathway(s) through which BvIR mediates expression of virulence determinants in *P. aeruginosa*, it was first decided to assess if BvIR fulfilled the expected molecular characteristics associated with a 'classical' LTTR. LTTRs are typically capable of negative auto-regulation and positively influence the transcription of divergently transcribed genes in close genomic proximity. These divergently transcribed targets are often responsible for the LTTRs, effect on virulence (Maddocks & Oyston, 2008; Schell, 1993). To investigate whether BvIR was capable of auto-regulation, the promoter region of *bvIR* was cloned into a plasmid, pMS402, which contains a promoterless *-lux* fusion. In a *bvIR* mutant expression of *bvIR* was significantly higher (Student's *t*-test, $P < 0.05$) than that observed in the wild-type over an 8 h time period (Fig. 3a), indicating that *bvIR* was capable of auto-regulation.

Divergently upstream from *bvIR* is PA14_26870 (*bvIA*), a gene assigned a hypothetical function. Bioinformatic analysis showed that *bvIR* and *bvIA* gene synteny is conserved in other *Pseudomonas* species. Moreover, a high degree of conservation is observed in the intergenic region between *bvIR* and *bvIA*, indicating that regulatory elements of significance may be present within this region. Quantitative real-time PCR was used to demonstrate that BvIR exerted a strong negative




Fig. 2. BvIR modulates virulence in the *Caenorhabditis elegans* model of infection. Percentage *C. elegans* survival is shown on the *y*-axis and length of survival is shown on the *x*-axis. The mean results of three independent biological experiments are shown. Between 45 and 60 L4 synchronized worms were used per strain for each biological replicate. The observed difference for strain PA14::*bvIR* pME*bvIR* is significant (Student's *t*-test, $P < 0.01$) for each time point of assay.

regulatory influence over *bvIA* (Student's *t*-test, $P < 0.05$) (Fig. 3b). The negative influence of BvIR on the expression of *bvIA* is contrary to the observed regulatory features typically assigned to an LTTR. This evidence suggests that BvIR may be an LTTR that functions predominantly as a transcriptional repressor, few of which have previously been described (Maddocks & Oyston, 2008).

BvIR exerts its regulatory influence over *bvIA* through direct binding to the *bvIR*–*bvIA* intergenic region

Typically LTTRs exhibit their regulatory influence over a divergently transcribed gene through direct binding (Maddocks & Oyston, 2008). A His-tagged BvIR expression construct was generated (pET28*abvIR*H6C) and the BvIR regulator was subsequently purified as a monomer of 34.5 kDa by nickel affinity column chromatography (Fig. S1). An EMSA was performed to assess if the transcriptional influence that BvIR was exerting over *bvIA* was due to direct binding. Purified His-tagged BvIR fusion protein caused a mobility shift in the presence of an infrared-labelled DNA probe spanning the *bvIR*–*bvIA* intergenic region (Fig. 4b). These data demonstrate that BvIR is binding to the *bvIR*–*bvIA* intergenic region. As LTTRs typically bind a specific motif, T-N₁₁-A, the *bvIR*–*bvIA* intergenic region was analysed for such a motif. A single T-N₁₁-A (TCCCGAATAGAGA) motif was identified in the *bvIR*–*bvIA* intergenic region (Fig. 4a). To investigate if this motif was essential for direct binding, EMSA was performed using a truncated *bvIR*–*bvIA* intergenic region, amplified using the




Fig. 3. (a) BvIR regulates *bvIA* expression levels. Quantitative real-time PCR was performed using primers specific to *bvIA*. Fold change in presented relative to the housekeeping gene *proC*. *Student's *t*-test, $P < 0.05$. (b) BvIR demonstrates negative auto-regulation. Expression of *bvIR* over time measured in relative light units using a modified pMS402 that contains a *bvIR* promoter-*lux* fusion conjugated to PA14 pME6032 and PA14 : : *bvIR* pME6032. All light readings were made relative to optical density. The data are the mean of three independent biological replicates.

primer set *bvIR/bvIA* IT IRF and *bvIR/bvIA* IT IRR, which did not contain this potential binding site. The purified His-tagged BvIR fusion protein did not cause a mobility shift in the presence of this amplicon encompassing the sequence from -31 to -249 bp downstream of the *bvIA* transcriptional start site (Fig. 4c), demonstrating that BvIR binding

requires the TCCCGAATAGAGA motif. As BvIR and BvIA are divergently transcribed the *bvIR-bvIA* intergenic region encompasses the promoter regions of both genes. Thus, the directing binding to this intergenic region is likely to be not only responsible for the effect of BvIR on *bvIA* transcription but also for the auto-regulation of *bvIR* expression. As *bvIA*




Fig. 4. Direct binding of BvIR to the *bvIA-bvIR* intergenic region. (a) The genomic location of both infrared-labelled fragments with respect to *bvIR* and *bvIA*. (b) His-tag-purified BvIR causes a mobility shift in the presence of the *bvIA* upstream region. (c) No shift was observed with a truncated *bvIA* upstream region which lacks the BvIR binding site. (d) Direct binding of BvIR to the *sigX-oprF* region. His-tag purified BvIR causes a mobility shift in the presence of the *sigX-oprF* intergenic region. The concentration of His-tagged BvIR used in each assay is indicated above the gel image. Infrared-labelled DNA at 10 fmol was used.

is a direct transcriptional target of BvlR it could be responsible for the phenotypes associated with a *bvlR* mutant. However, a *bvlA* mutant failed to influence T3S, attachment or tight microcolony formation, indicating that *bvlA* is not responsible for the BvlR-associated phenotypes identified in this study (data not shown). That *bvlA* does not appear to play a role in any of the identified BvlR phenotypes suggests that other targets of BvlR may be responsible for the observed phenotypes, consistent with the emerging role of LTTRs as global regulators of gene expression.

BvlR regulation controls virulence-associated gene expression

To identify other transcriptional targets of BvlR that could explain the observed phenotypes, global transcriptomic analysis was performed. To ensure isogenicity, the *bvlR* mutant was compared with the complemented strain for transcriptomic analysis. Approximately 5.6% of the genes (307 genes of the 5500 *P. aeruginosa* PAO1 probe sets on the microarray) demonstrated significantly altered expression greater than twofold (moderated *t*-test, $P < 0.05$) (Table S2). The changes in gene expression ranged from -10.6 - to -2 -fold. BvlR negatively influenced the expression of all of the genes in the transcriptome dataset, further emphasizing BvlR's potential role as a transcriptional repressor. A number of genes associated with virulence were repressed by BvlR (Table 2), confirming the influence of BvlR on the pathogenicity of *P. aeruginosa*. Genes involved in metabolite transportation were also highly represented within the

transcriptome dataset. To establish further the role of BvlR, the transcriptome profile was investigated for links between the changes in gene expression and *bvlR*-associated virulence phenotypes.

BvlR modulates expression genes associated with surface attachment. Expression of key genes of the *cupA* operon was induced in the *bvlR* mutant. The *cupA* operon encodes components and assembly factors of a fimbrial structure that are known to play a key role in surface attachment. It has been shown that increased expression of this operon can lead to a hyperattachment phenotype (Kulasekara *et al.*, 2005; Meissner *et al.*, 2007; Vallet *et al.*, 2001). This corresponds with the increased attachment observed in a *bvlR* mutant. Quantitative real-time PCR analysis of *cupA2* and *cupA3* confirmed the initial finding of the transcriptome dataset that the *cupA* operon was indeed upregulated in a *bvlR* mutant (Fig. 5a). It is thought that expression of the *cup* operon is specific to particular niches such as attachment to specific biological surfaces (Kuehn *et al.*, 1992). A number of genes associated with alginate biosynthesis were also modulated in the transcriptome. This finding was confirmed by quantitative real-time PCR using primers specific to *algK* (Fig. 5b). It is known that alginate is capable of modulating biofilm architecture, although it is not essential for biofilm formation (Lizewski *et al.*, 2004). Attachment to a substratum has been shown to induce expression of genes in the alginate biosynthetic pathway (Boyd & Chakrabarty, 1994). Based on the influence of surface attachment on alginate expression, the increased expression of key genes in

Table 2. Virulence genes negatively regulated greater than twofold by BvlR identified through microarray analysis (moderated *t*-test, $P < 0.05$)

ORF ID	Gene name	Description	Fold change
Genes associated with attachment and biofilm			
PA3541	<i>alg8</i>	Alginate biosynthesis protein	2.5
PA3548	<i>algI</i>	Alginate O-acetyltransferase	2.1
PA3549	<i>algJ</i>	Alginate O-acetyltransferase	2.0
PA3543	<i>algK</i>	Alginate biosynthetic protein	10.6
PA3547	<i>algL</i>	Poly(β -D-mannuronate) lyase precursor	2.1
PA2129	<i>cupA2</i>	Chaperone	2.2
PA2132	<i>cupA5</i>	Chaperone	2.4
PA4084	<i>cupB3</i>	Usher	7.2
PA4083	<i>cupB4</i>	Chaperone	2.6
PA4082	<i>cupB5</i>	Adhesive protein	4.1
PA4081	<i>cupB6</i>	Fimbrial subunit	3.2
PA2235	<i>pslE</i>	Exopolysaccharide biosynthesis	2.3
PA2236	<i>pslF</i>	Exopolysaccharide biosynthesis	2.4
Genes associated with virulence			
PA4813	<i>lipC</i>	Lipase	8.4
PA3319	<i>plcN</i>	Non-haemolytic phospholipase C precursor	2.6
PAO843	<i>plcR</i>	Phospholipase accessory protein	2.0
PA1148	<i>toxA</i>	Exotoxin A precursor	2.4
PAO707	<i>toxR</i>	Transcriptional regulator	2.4




Fig. 5. BvIR is a repressor of virulence-associated gene expression. (a) BvIR negatively regulates *cupA* gene expression. Expression of key genes in the *cupA* operon was assessed using quantitative real-time PCR. Primers specific to *cupA2* and *cupA3* demonstrated a significant repression of operon expression when *bvIR* is expressed (Student's *t*-test, $P < 0.05$). (b) BvIR modulates *algK* transcription. Quantitative real-time PCR was used to determine that expression of *algK* is reduced sixfold when an active copy of *bvIR* is expressed (Student's *t*-test, $P < 0.05$). (c) BvIR negatively regulates *toxA* expression. Quantitative real-time PCR analysis of exotoxin A production demonstrates that expression of *bvIR* leads to a 14-fold reduction in *toxA* transcript levels (Student's *t*-test, $P < 0.05$). RNA was extracted from exponential-phase cultures. All values are presented relative to the housekeeping gene *proC*. Data shown are mean values of three biological experiments with SD as error bars. *Student's *t*-test, $P < 0.05$.

the alginate biosynthetic operon in the *bvIR* mutant may be a result of the increased surface attachment associated with the *bvIR* mutant.

BvIR negatively regulates exotoxin A expression.

BvIR expression also modulated *toxA* expression in the transcriptome dataset. Exotoxin A (*toxA*) represents one of the key virulence factors through which *P. aeruginosa* is capable of killing *C. elegans* (Fogle *et al.*, 2002; Matsumoto *et al.*, 1999). ToxA is an ADP-ribosyltransferase that can inhibit protein synthesis (Iglewski & Kabat, 1975). Various animal models have demonstrated the importance of exotoxin A in *P. aeruginosa* infection, with *toxA* mutants typically being less virulent than their wild-type counterparts (Fogle *et al.*, 2002; Matsumoto *et al.*, 1999). To validate the transcriptome results, expression levels of exotoxin A were

determined using quantitative real-time PCR analysis. A 14-fold reduction in *toxA* levels was observed when BvIR is present (Student's *t*-test, $P < 0.05$) (Fig. 5c). The observed effect of BvIR on pathogenicity in the *C. elegans* model is probably mediated through the reduction in exotoxin A levels. The positive regulator of exotoxin A, ToxR, was also found to be downregulated twofold in the transcriptome dataset, suggesting that BvIR regulatory influence over *toxA* may occur through cross-talk between these distinct transcriptional regulators.

The transcriptome dataset highlights a network of genes that are transcriptionally repressed by BvIR. Although this further supports the evidence that *bvIR* encodes an LTTR repressor that is capable of downregulating genes associated with acute virulence, while promoting the formation of the self-aggregating tight microcolonies of a mucoid CF

lung, the molecular interactions underpinning this regulation need to be established.

BvIR role in virulence may be both direct and indirect

To determine the pathway through which BvIR exerts its effects on gene expression linked to virulence, candidate promoters were examined for binding affinity with purified BvIR protein. A dual approach was taken to the selection of these promoters, focusing on (a) virulence-associated genes from the transcriptome profiling and on (b) those with highly similar T-N₁₁-A motifs to the BvIR box. Bioinformatic analysis of the *P. aeruginosa* genome sequence failed to identify complete BvIR binding motifs, other than that in the *bvIR*-*bvIA* intergenic region. By systematically reducing the stringency to allow for mismatches, a bank of potential BvIR binding candidates was generated, which included intergenic regions upstream of virulence-associated genes such as *exsC*, *oprF* and *algQ* (Fig. S2). In addition, several promoters in which motifs closely related to the BvIR motif were identified were also included in this analysis, although these loci were not present in the transcriptome dataset.

Infrared primers were designed to each of the regions that contained a partial BvIR binding motif. These regions were then amplified and EMSA binding analysis was performed (Fig. S3). Purified BvIR was seen to cause a mobility shift for one of the potential binding targets, the *sigX*-*oprF* intergenic region (Fig. 4d). The BvIR binding motif in this *sigX*-*oprF* intergenic region had among the highest sequence similarity of all the potential candidates, with 11 of the 13 bases being conserved with the BvIR binding motif in the *bvIR*-*bvIA* intergenic region. While this might suggest that the interaction of purified BvIR protein with DNA is highly specific in the absence of a recognized ligand, it must be noted that other promoters with the same degree of conservation did not bind BvIR (Fig. S3). Perhaps surprisingly, although consistent with the transcriptome profiling, no significant difference in *oprF* transcription levels was observed between PA14 pME6032, PA14::*bvIR* pME6032 and PA14::*bvIR* pME*bvIR* in LB broth (data not shown).

Apart from the *sigX*-*oprF* promoter region, BvIR was not found to interact with the other promoters tested in this study, even though several contained highly similar motifs to that in the *bvIR*-*bvIA* intergenic region to which BvIR has been shown to bind. These include the promoters of several virulence-associated genes which were altered in the transcriptome profile, suggesting that at least some of the effects attributed to BvIR may be the result of indirect regulation. Notwithstanding this, it is well known that the DNA binding specificity and transcriptional influence of many LTTRs are significantly altered by the presence of a specific ligand (Maddocks & Oyston, 2008). The strong phenotypic profile associated with a BvIR mutant suggests that BvIR's direct binding targets are indeed likely to

extend beyond those confirmed *in vitro*. Future work will focus on the identification of a specific ligand which may be central to the interaction of BvIR with direct transcriptional targets.

DISCUSSION

The data presented demonstrate that the LTTR BvIR is a novel virulence regulator that plays a key modulatory role in the expression of a wide range of virulence determinants. BvIR is one of the few LTTRs whose regulation is altered in response to eukaryotic cells (Frisk *et al.*, 2004), indicating a potential role for BvIR in pathogenicity. *P. aeruginosa* infection is characterized by two distinct phases, the acute state and chronic state. Acute infection involves the production of a wide range of virulence determinants and a motile mode of growth. BvIR expression was shown to repress the T3SS, one of the main exotoxin secretion systems associated with acute infection (Jin *et al.*, 2011; Mulcahy *et al.*, 2006; Yahr *et al.*, 1995; Yahr & Wolfgang, 2006). Whereas the T3SS was induced in a *bvIR* mutant, the ability of the mutant to form tight microcolonies was lost. This is not surprising as the T3SS and biofilm formation are often inversely regulated (Furukawa *et al.*, 2006).

Tight microcolony formation is a configuration of biofilm formation associated with the CF lung. This mode of biofilm formation differs from typical biofilm formation as it does not require a surface to attach to. Instead, cells self-aggregate to form free-floating biofilm-like structures. Tight microcolony formation is particularly relevant to the CF lung as it has been shown that 95% of *P. aeruginosa* found in the CF lung are present at a distance greater than 5 µm from the epithelial cell surface in non-surface-attached tight microcolonies (Worlitzsch *et al.*, 2002). The tight microcolony form of biofilm formation may have very different phenotypic and genetic properties from the classically studied surface-attached biofilm. The influence of BvIR on this phenotype is probably mediated through its role in repressing *cupA*-associated fimbrial-based surface attachment (Lizewski *et al.*, 2004; Mulcahy & Lewenza, 2011; Vallet *et al.*, 2001). Surface attachment is upregulated in a *bvIR* mutant most likely through the increased transcription of the *cupA* operon. While fimbrial attachment is key to the initial stages of biofilm formation on a surface, it has been shown to be downregulated as the biofilm formation process proceeds (Lizewski *et al.*, 2004; Mulcahy & Lewenza, 2011; Vallet *et al.*, 2001). The identification of BvIR as a regulator of this form of biofilm adds another novel gene to the complex regulatory network already involved in controlling biofilm formation. BvIR is the first LTTR to be described with a role in tight microcolony formation.

Experiments with the *C. elegans* model of infection demonstrated that the presence of BvIR reduces the capacity of *P. aeruginosa* to establish acute infection. BvIR was shown to significantly reduce *toxA* expression, one of the key virulence determinants through which *P. aeruginosa* is capable of

killing *C. elegans* (Fogle *et al.*, 2002; Matsumoto *et al.*, 1999). Furthermore, the identification of homologues of BvIR in a wide variety of respiratory pathogens may indicate a positive selection for BvIR consistent with its potential role in infection in the niche environment of the lung (Fig. S4).

BvIR is the first LTTR described in *P. aeruginosa* to function predominantly as a transcriptional repressor. BvIR fulfils a number of the 'classical' features associated with LTTRs, such as the ability to negatively auto-regulate its own expression, and to regulate expression of a divergently transcribed gene, *bvIA* (Maddocks & Oyston, 2008; Schell, 1993). LTTRs are typically associated with positive transcriptional regulation of divergent targets. BvIR exhibits an unusual mode of action in its regulation of *BvIA*, as it negatively affects its expression. BvIR was found to bind to the *bvIR–bvIA* intergenic region, specifically to the TCCGAATAGAGA motif, consistent with the classic LTTR T-N₁₁-A binding box (Parsek *et al.*, 1994). Additional complete BvIR binding motifs were not identified in the *P. aeruginosa* genome sequence. This suggests that redundancy may exist with some of the nucleotides within the motif. Bioinformatic analysis identified a number of partially conserved motifs within the *P. aeruginosa* genome sequence. Of these potential binding targets, BvIR was shown to directly bind to the *sigX–oprF* intergenic region. In spite of the specific *in vitro* interaction between BvIR and this promoter region, expression was not altered in the mutant or complemented strain. This may be due to the complex nature of *oprF* transcriptional regulation, with four different promoters all having a significant impact on *oprF* transcription with varying degrees of importance depending on a range of environmental and metabolic conditions (Bouffartigues *et al.*, 2012). It is interesting to note that *oprF* is upregulated in contact with sputum, and plays a crucial role in the ability of *P. aeruginosa* to form tight micro-colonies within ASM. Together, this suggests that a potential regulatory interplay may exist between *oprF* and BvIR in specific environments such as the CF lung. Outside of the evidence presented of the *bvIR–bvIA* and *sigX–oprF* intergenic regions being direct binding targets for purified BvIR, partially conserved BvIR binding motifs were also identified upstream of a number of genes that were modulated in the transcriptome, such as *plcR*, *antA* and *coxB*, suggesting these may also be BvIR direct binding targets but only in the presence of a ligand (Fig. S2). Future work will focus on distinguishing the direct and indirect downstream regulatory pathways that are influenced by BvIR.

In agreement with the data from the molecular analysis of BvIR, global transcriptome analysis highlighted the potential role of BvIR as a transcriptional repressor, as it was shown to downregulate the expression of its targets. A number of transcriptional regulators were seen to be modulated within the transcriptome dataset, although searches of the available literature did not establish a direct link between these regulators and the virulence phenotypes associated with BvIR. Note, however, that BvIR

expression did repress the transcription of another predicted LTTR, PA14_27400, and that phylogenetic analysis of the evolution of LTTR proteins in *P. aeruginosa* clustered both PA2877 and PA2838 (PA14_27400) together in a single clade (Reen *et al.*, 2013b). An interesting finding in that paper was the interfacing of clustered regulatory networks, suggesting that a novel regulatory cascade may exist between these LTTRs. Future work will focus on the potentially ligand-specific interaction of BvIR with other transcriptional regulators that may underpin the virulence-associated role of BvIR in *P. aeruginosa*.

The evidence presented highlights the significant impact this previously uncharacterized regulator has in modulating the pathogenic potential of *P. aeruginosa*, significantly influencing the production of acute virulence determinants such as exotoxin A production and the T3SS. It is also shown to have a significant impact on surface attachment and a CF lung-specific mode of biofilm formation. The influence that BvIR has on *P. aeruginosa* virulence is likely to be the result of both direct and indirect effects and further work is needed to define the hierarchical pathway through which this key regulatory protein impacts on virulence. However, taken together with the previous observation of the upregulation of BvIR in response to contact with epithelial cells (Frisk *et al.*, 2004) the data suggest that BvIR is a key component of the regulatory interplay in the pathogen–host interactome.

ACKNOWLEDGEMENTS

This research was supported in part by grants awarded by the Science Foundation of Ireland (07/IN.1/B948, 12/TIDA/B2411, 12/TIDA/B2405, 09/RFP/BMT 2350, SSPC212/RC/2275); the Department of Agriculture, Fisheries and Food (FIRM/RSF/CoFoRD; DAFF11/F/009MabS); the Environmental Protection Agency (EPA 2008-PhD/S-2); the Irish Research Council for Science, Engineering and Technology (PD/2011/2414; RS/2010/2413); the European Commission (FP7-PEOPLE-2013-ITN, 607786; FP7-KBBE-2012-6, FP7-KBBE-2012-6, Marie Curie 256596); Marine Microbial Biodiversity, Bioinformatics and Biotechnology (MICRO B3) (OCEAN 2012 287589), Marine Micro-organisms: Cultivation Methods for improving their Biotechnological Applications (MACUMBA) (CP-TP 311975), Increasing Value and Flow in the Marine Biodiscovery Pipeline (PharmaSea) (CP-TP 312184) and the Marine Institute (Beaufort award C2CRA 2007/082); Teagasc (Walsh Fellowship 2013) and the Health Research Board (HRA/2009/146).

REFERENCES

- Blier, A. S., Veron, W., Bazire, A., Gerault, E., Taupin, L., Vieillard, J., Rehel, K., Dufour, A., Le Derf, F. & other authors (2011). C-type natriuretic peptide modulates quorum sensing molecule and toxin production in *Pseudomonas aeruginosa*. *Microbiology* **157**, 1929–1944.
- Bouffartigues, E., Gicquel, G., Bazire, A., Bains, M., Maillot, O., Vieillard, J., Feuilloley, M. G., Orange, N., Hancock, R. E. & other authors (2012). Transcription of the *oprF* gene of *Pseudomonas aeruginosa* is dependent mainly on the SigX sigma factor and is sucrose induced. *J Bacteriol* **194**, 4301–4311.

- Boyd, A. & Chakrabarty, A. M. (1994). Role of alginate lyase in cell detachment of *Pseudomonas aeruginosa*. *Appl Environ Microbiol* **60**, 2355–2359.
- Boyer, H. W. & Roulland-Dussoix, D. (1969). A complementation analysis of the restriction and modification of DNA in *Escherichia coli*. *J Mol Biol* **41**, 459–472.
- Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding. *Anal Biochem* **72**, 248–254.
- de Lorenzo, V. & Timmis, K. N. (1994). Analysis and construction of stable phenotypes in gram-negative bacteria with Tn5- and Tn10-derived minitransposons. *Methods Enzymol* **235**, 386–405.
- Delic-Attree, I., Toussaint, B., Garin, J. & Vignais, P. M. (1997). Cloning, sequence and mutagenesis of the structural gene of *Pseudomonas aeruginosa* CysB, which can activate *algD* transcription. *Mol Microbiol* **24**, 1275–1284.
- Duan, K. & Surette, M. G. (2007). Environmental regulation of *Pseudomonas aeruginosa* PAO1 Las and Rhl quorum-sensing systems. *J Bacteriol* **189**, 4827–4836.
- Fogle, M. R., Griswold, J. A., Oliver, J. W. & Hamood, A. N. (2002). Anti-ETA IgG neutralizes the effects of *Pseudomonas aeruginosa* exotoxin A. *J Surg Res* **106**, 86–98.
- Frisk, A., Schurr, J. R., Wang, G., Bertucci, D. C., Marrero, L., Hwang, S. H., Hassett, D. J. & Schurr, M. J. (2004). Transcriptome analysis of *Pseudomonas aeruginosa* after interaction with human airway epithelial cells. *Infect Immun* **72**, 5433–5438.
- Furukawa, S., Kuchma, S. L. & O'Toole, G. A. (2006). Keeping their options open: acute versus persistent infections. *J Bacteriol* **188**, 1211–1217.
- Gjermansen, M., Ragas, P., Sternberg, C., Molin, S. & Tolker-Nielsen, T. (2005). Characterization of starvation-induced dispersion in *Pseudomonas putida* biofilms. *Environ Microbiol* **7**, 894–906.
- Harrison, F. (2007). Microbial ecology of the cystic fibrosis lung. *Microbiology* **153**, 917–923.
- Heeb, S., Itoh, Y., Nishijyo, T., Schneider, U., Keel, C., Wade, J., Walsh, U., O'Gara, F. & Haas, D. (2000). Small, stable shuttle vectors based on the minimal pVS1 replicon for use in gram-negative, plant-associated bacteria. *Mol Plant Microbe Interact* **13**, 232–237.
- Iglewski, B. H. & Kabat, D. (1975). NAD-dependent inhibition of protein synthesis by *Pseudomonas aeruginosa* toxin. *Proc Natl Acad Sci U S A* **72**, 2284–2288.
- Jin, Y., Yang, H., Qiao, M. & Jin, S. (2011). MexT regulates the type III secretion system through MexS and PtrC in *Pseudomonas aeruginosa*. *J Bacteriol* **193**, 399–410.
- Keen, N. T., Tamaki, S., Kobayashi, D. & Trollinger, D. (1988). Improved broad-host-range plasmids for DNA cloning in Gram-negative bacteria. *Gene* **70**, 191–197.
- Koch, C. & Høiby, N. (1993). Pathogenesis of cystic fibrosis. *Lancet* **341**, 1065–1069.
- Kuehn, M. J., Heuser, J., Normark, S. & Hultgren, S. J. (1992). P pili in uropathogenic *E. coli* are composite fibres with distinct fibrillar adhesive tips. *Nature* **356**, 252–255.
- Kulasekara, H. D., Ventre, I., Kulasekara, B. R., Lazdunski, A., Filloux, A. & Lory, S. (2005). A novel two-component system controls the expression of *Pseudomonas aeruginosa* fimbrial cup genes. *Mol Microbiol* **55**, 368–380.
- Liberati, N. T., Urbach, J. M., Miyata, S., Lee, D. G., Drenkard, E., Wu, G., Villanueva, J., Wei, T. & Ausubel, F. M. (2006). An ordered, nonredundant library of *Pseudomonas aeruginosa* strain PA14 transposon insertion mutants. *Proc Natl Acad Sci U S A* **103**, 2833–2838.
- Lizewski, S. E., Schurr, J. R., Jackson, D. W., Frisk, A., Carterson, A. J. & Schurr, M. J. (2004). Identification of AlgR-regulated genes in *Pseudomonas aeruginosa* by use of microarray analysis. *J Bacteriol* **186**, 5672–5684.
- Lyczak, J. B., Cannon, C. L. & Pier, G. B. (2002). Lung infections associated with cystic fibrosis. *Clin Microbiol Rev* **15**, 194–222.
- Maddocks, S. E. & Oyston, P. C. (2008). Structure and function of the LysR-type transcriptional regulator (LTTR) family proteins. *Microbiology* **154**, 3609–3623.
- Matsumoto, T., Furuya, N., Tateda, K., Miyazaki, S., Ohno, A., Ishii, Y., Hirakata, Y. & Yamaguchi, K. (1999). Effect of passive immunotherapy on murine gut-derived sepsis caused by *Pseudomonas aeruginosa*. *J Med Microbiol* **48**, 765–770.
- Meissner, A., Wild, V., Simm, R., Rohde, M., Erck, C., Bredenbruch, F., Morr, M., Römling, U. & Häussler, S. (2007). *Pseudomonas aeruginosa* *cupA*-encoded fimbriae expression is regulated by a GGDEF and EAL domain-dependent modulation of the intracellular level of cyclic diguanylate. *Environ Microbiol* **9**, 2475–2485.
- Miller, J. H. (1972). *Experiments in Molecular Genetics*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
- Mulcahy, H. & Lewenza, S. (2011). Magnesium limitation is an environmental trigger of the *Pseudomonas aeruginosa* biofilm lifestyle. *PLoS ONE* **6**, e23307.
- Mulcahy, H., O'Callaghan, J., O'Grady, E. P., Adams, C. & O'Gara, F. (2006). The posttranscriptional regulator RsmA plays a role in the interaction between *Pseudomonas aeruginosa* and human airway epithelial cells by positively regulating the type III secretion system. *Infect Immun* **74**, 3012–3015.
- O'Toole, G. A. & Kolter, R. (1998). The initiation of biofilm formation in *Pseudomonas fluorescens* WCS365 proceeds via multiple, convergent signaling pathways: a genetic analysis. *Mol Microbiol* **28**, 449–461.
- Parsek, M. R., Ye, R. W., Pun, P. & Chakrabarty, A. M. (1994). Critical nucleotides in the interaction of a LysR-type regulator with its target promoter region. *catBC* promoter activation by CatR. *J Biol Chem* **269**, 11279–11284.
- Reen, F. J., Barret, M., Fargier, E., O'Muinneacháin, M. & O'Gara, F. (2013a). Molecular evolution of LysR-type transcriptional regulation in *Pseudomonas aeruginosa*. *Mol Phylogenet Evol* **66**, 1041–1049.
- Reen, F. J., Haynes, J. M., Mooij, M. J. & O'Gara, F. (2013b). A non-classical LysR-type transcriptional regulator PA2206 is required for an effective oxidative stress response in *Pseudomonas aeruginosa*. *PLoS ONE* **8**, e54479.
- Sambrook, J. & Russell, D. W. (2001). *Molecular Cloning: a Laboratory Manual*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory.
- Schell, M. A. (1993). Molecular biology of the LysR family of transcriptional regulators. *Annu Rev Microbiol* **47**, 597–626.
- Spaink, H. P., Okker, R. J. H., Wiffelman, C. A., Pees, E. & Lugtenberg, B. J. J. (1987). Promoters in the nodulation region of the *Rhizobium leguminosarum* Sym plasmid pRL1J1. *Plant Mol Biol* **9**, 27–39.
- Sriramulu, D. D., Lünsdorf, H., Lam, J. S. & Römling, U. (2005). Microcolony formation: a novel biofilm model of *Pseudomonas aeruginosa* for the cystic fibrosis lung. *J Med Microbiol* **54**, 667–676.
- Sulston, J. & Hodgkin, J. (1988). *The Nematode Caenorhabditis elegans*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
- Tian, Z. X., Fargier, E., Mac Aogáin, M., Adams, C., Wang, Y. P. & O'Gara, F. (2009). Transcriptome profiling defines a

novel regulon modulated by the LysR-type transcriptional regulator MexT in *Pseudomonas aeruginosa*. *Nucleic Acids Res* **37**, 7546–7559.

Vallet, I., Olson, J. W., Lory, S., Lazdunski, A. & Filloux, A. (2001). The chaperone/usher pathways of *Pseudomonas aeruginosa*: identification of fimbrial gene clusters (*cup*) and their involvement in biofilm formation. *Proc Natl Acad Sci U S A* **98**, 6911–6916.

Wade, D. S., Calfee, M. W., Rocha, E. R., Ling, E. A., Engstrom, E., Coleman, J. P. & Pesci, E. C. (2005). Regulation of *Pseudomonas* quinolone signal synthesis in *Pseudomonas aeruginosa*. *J Bacteriol* **187**, 4372–4380.

Worlitzsch, D., Tarran, R., Ulrich, M., Schwab, U., Cekici, A., Meyer, K. C., Birrer, P., Bellon, G., Berger, J. & other authors (2002). Effects of reduced mucus oxygen concentration in airway *Pseudomonas* infections of cystic fibrosis patients. *J Clin Invest* **109**, 317–325.

Yahr, T. L. & Wolfgang, M. C. (2006). Transcriptional regulation of the *Pseudomonas aeruginosa* type III secretion system. *Mol Microbiol* **62**, 631–640.

Yahr, T. L., Hovey, A. K., Kulich, S. M. & Frank, D. W. (1995). Transcriptional analysis of the *Pseudomonas aeruginosa* exoenzyme S structural gene. *J Bacteriol* **177**, 1169–1178.

Edited by: J. Kok